Haleon PLC (GB:HLN) has released an update.
Haleon PLC has successfully completed the sale of its nicotine replacement therapy (NRT) business outside the US to Dr. Reddy’s Laboratories SA for a deal worth up to £500 million. The transaction includes a £458 million upfront payment, with additional performance-based payments scheduled for 2025 and the first half of 2026. This strategic move aligns with Haleon’s focus on leading the consumer health market with its diverse portfolio of established brands.
For further insights into GB:HLN stock, check out TipRanks’ Stock Analysis page.
